跳到正文
Nature 干细胞主题·· 2 天前精选AI 评分62

研究显示Elp1为髓系分化与脑内再定植所必需

Elp1 is required for myeloid differentiation and brain repopulation

AI 导读

斯坦福大学Wernig实验室在Nature发表研究，题为Elp1 is required for myeloid differentiation and brain repopulation，通过CRISPR敲除筛选和小鼠移植实验表明Elp1缺失影响髓系细胞分化及脑内再定植。

正文 · AI 翻译

译文尚不完整，完整内容请切换到原文。

数据可用性

本研究生成和分析的小鼠测序数据集可从基因表达综合数据库（Gene Expression Omnibus）83获取，登录号为GSE255732、GSE255735和GSE255893。小鼠参考基因组来自www.gencodegenes.org，小鼠参考蛋白质组来自www.uniprot.org。基因集来自www.gsea-msigdb.org和www.geneontology.org。MS蛋白质组学数据已通过PRIDE85合作数据库存入ProteomeXchange84联盟，数据集标识符为PXD049985。 源数据随本文提供。

代码可用性

计算分析使用免费可用的软件包进行，详见方法。如需复制本研究所需的额外信息，可向通讯作者提出合理请求后获取。

参考文献

  1. Biffi, A. et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest. 116, 3070–3082 (2006).

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  2. Colella, P. et al. CNS-wide repopulation by hematopoietic-derived microglia-like cells corrects progranulin deficiency in mice. Nat. Commun. 15, 5654 (2024).

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  3. Mader, M. M.-D. et al. Therapeutic genetic restoration through allogeneic brain microglia replacement. Nature 646, 903–912 https://doi.org/10.1038/s41586-025-09461-6 (2025).

    文章  PubMed  CAS  Google Scholar 

  4. Frosch, M. et al. Microglia–neuron crosstalk via Hex–GM2–MGL2 maintains brain homeostasis. Nature 646, 913–924 https://doi.org/10.1038/s41586-025-09477-y (2025).

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  5. Tsourmas, K. I. et al. Microglial replacement in a Sandhoff disease mouse model reveals myeloid-derived β-hexosaminidase is necessary for neuronal health. Nat. Commun. 16, 7994 (2025).

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  6. Aisenberg, W. H. et al. Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease. Immunity 0, 1254–1268 (2025).

    文章  CAS  Google Scholar 

  7. Wu, J. 等。小胶质细胞替换可阻止小鼠和人类小胶质细胞病的进展。Science 389, eadr1015 (2025)。

    文章  PubMed  CAS  Google Scholar 

  8. Ginhoux, F. 等。命运图谱分析揭示成体小胶质细胞来源于原始巨噬细胞。Science 330, 841–845 (2010)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  9. Priller, J. 等。将基因修饰的造血细胞靶向中枢神经系统：利用绿色荧光蛋白揭示小胶质细胞植入。Nat. Med. 7, 1356–1361 (2001)。

    文章  PubMed  CAS  Google Scholar 

  10. Mildner, A. 等。成体脑中的小胶质细胞仅在特定宿主条件下来源于 Ly-6ChiCCR2+ 单核细胞。Nat. Neurosci. 10, 1544–1553 (2007)。

    文章  PubMed  CAS  Google Scholar 

  11. Kierdorf, K., Katzmarski, N., Haas, C. A. & Prinz, M. 在无辐照或联体共生偏倚的情况下骨髓细胞向脑内的募集。PLoS ONE 8, e58544 (2013)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  12. Capotondo, A. 等。脑室内递送造血祖细胞可导致小胶质细胞样细胞快速且稳固的植入。Sci. Adv. 3, e1701211 (2017)。

    文章  ADS  PubMed  PubMed Central  Google Scholar 

  13. Hohsfield, L. A. 等。外周骨髓来源髓系细胞在中枢神经系统内长期且全脑定植的影响。J. Neuroinflammation 17, 279 (2020)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  14. Xu, Z. 等。中枢神经系统中小胶质细胞替换的有效策略。Cell Rep. 32, 108041 (2020)。

    文章  PubMed  CAS  Google Scholar 

  15. Shibuya, Y. 等。通过全中枢神经系统小胶质细胞替换治疗遗传性脑病。Sci. Transl. Med. 14, eabl9945 (2022)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  16. Sailor, K. A. 等。造血干细胞移植化疗导致小胶质细胞衰老及外周巨噬细胞在脑内植入。Nat. Med. 28, 517–527 (2022)。

    文章  PubMed  CAS  Google Scholar 

  17. Shemer, A. 等。移植的脑实质巨噬细胞在转录组、染色质景观和对刺激的反应上与小胶质细胞不同。Nat. Commun. 9, 5206 (2018)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  18. Cronk, J. C. 等。外周来源的巨噬细胞可以不依赖辐照而植入大脑，并保持与小胶质细胞不同的身份。J. Exp. Med. 215, 1627–1647 (2018)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  19. Elmore, M. R. P. 等。集落刺激因子1受体信号是小胶质细胞存活所必需的，并揭示了成年大脑中的小胶质细胞祖细胞。Neuron 82, 380–397 (2014)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  20. Shalem, O., Sanjana, N. E. & Zhang, F. 使用CRISPR–Cas9进行高通量功能基因组学。Nat. Rev. Genet. 16, 299–311 (2015)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  21. Osawa, M., Hanada, K., Hamada, H. & Nakauchi, H. 单个CD34低/阴性造血干细胞长期淋巴造血重建。Science 273, 242–245 (1996)。

    文章  ADS  PubMed  CAS  Google Scholar 

  22. Wilkinson, A. C. 等。长期离体造血干细胞扩增允许非清髓性移植。Nature 571, 117–121 (2019)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  23. Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M.-D. & Wernig, M. 一种在阿尔茨海默病小鼠模型中恢复小胶质细胞Trem2功能的细胞治疗方法。Cell Stem Cell 30, 1043–1053 (2023)。

    文章  PubMed  CAS  Google Scholar 

  24. Mader, M. M.-D. 髓系细胞替代在慢性实验性自身免疫性脑脊髓炎中具有神经保护作用。Nat. Neurosci. 27, 901–912 https://doi.org/10.1038/s41593-024-01609-3 (2024)。

    文章  PubMed  CAS  Google Scholar 

  25. Chadarevian, J. P. 等。工程化抗抑制剂人CSF1R变体用于小胶质细胞替代。J. Exp. Med. 220, e20220857 (2023)。

    文章  PubMed  CAS  Google Scholar 

  26. Soucie, E. L. 等。谱系特异性增强子激活巨噬细胞和胚胎干细胞中的自我更新基因。Science 351, aad5510 (2016)。

    文章  PubMed  PubMed Central  Google Scholar 

  27. Wilson, A. 等。c-Myc 控制造血干细胞自我更新与分化之间的平衡。Genes Dev. 18, 2747–2763 (2004)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  28. Chen, W. Y. 等。肿瘤抑制因子 HIC1 直接调控 SIRT1 以调节 p53 依赖性 DNA 损伤反应。Cell 123, 437–448 (2005)。

    文章  PubMed  CAS  Google Scholar 

  29. Wang, Z. 等。新型 GATA1 相互作用蛋白 HES6 是人红细胞生成必需的转录辅因子。Nucleic Acids Res. 51, 4774–4790 (2023)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  30. Whitfield, M. L., George, L. K., Grant, G. D. & Perou, C. M. 增殖的共同标志物。Nat. Rev. Cancer 6, 99–106 (2006)。

    文章  PubMed  CAS  Google Scholar 

  31. Morgens, D. W. 等。利用 Cas9 毒性在高通量筛选中进行脱靶活性的全基因组规模测量。Nat. Commun. 8, 15178 (2017)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  32. Gallouet, A.-S. 等。巨噬细胞的产生和活化依赖于 TRIM33。Oncotarget 8, 5111–5122 (2017)。

    文章  PubMed  PubMed Central  Google Scholar 

  33. Shankar, A. 等。体内 CRISPR 筛选鉴定 SAGA 复合体成员为造血的关键调控因子。Nat. Commun. 17, 1756 (2026)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  34. Anderson, S. L. 等。家族性自主神经功能障碍由 IKAP 基因突变引起。Am. J. Hum. Genet. 68, 753–758 (2001)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  35. Slaugenhaupt, S. A. 等。IKBKAP 基因中剪接突变的组织特异性表达导致家族性自主神经功能障碍。Am. J. Hum. Genet. 68, 598–605 (2001)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  36. Waszak, S. M. 等。Sonic Hedgehog 髓母细胞瘤中的种系 Elongator 突变。Nature 580, 396–401 (2020)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  37. Kojic, M. 等。一种新的 ELP1 突变损害 Elongator 复合体的功能并导致严重的神经发育表型。J. Hum. Genet. 68, 445–453 (2023)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  38. George, L. 等。家族性自主神经功能障碍模型揭示 Ikbkap 缺失导致 Pax3+ 祖细胞和外周神经元凋亡。Proc. Natl Acad. Sci. USA 110, 18698–18703 (2013)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  39. Yona, S. 等。命运图谱揭示稳态下单核细胞和组织巨噬细胞的起源与动态。Immunity 38, 79–91 (2013)。

    文章  PubMed  CAS  Google Scholar 

  40. Sánchez-Aguilera, A. 等。雌激素信号选择性诱导造血祖细胞和髓系肿瘤凋亡而不损害稳态造血。Cell Stem Cell 15, 791–804 (2014)。

    文章  PubMed  Google Scholar 

  41. Patel, A. A., Ginhoux, F. & Yona, S. 单核细胞、巨噬细胞、树突状细胞和中性粒细胞：健康和疾病中寿命动力学的最新进展。Immunology 163, 250–261 (2021)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  42. Zhan, L. 等。自我更新的小胶质细胞近端再定植重建成年小鼠脑中的小胶质细胞稳态。PLoS Biol. 17, e3000134 (2019)。

    文章  PubMed  PubMed Central  Google Scholar 

  43. Goffena, J. 等。Elongator 和密码子偏好调节哺乳动物外周神经元中的蛋白质水平。Nat. Commun. 9, 889 (2018)。

    文章  ADS  PubMed  PubMed Central  Google Scholar 

  44. Xu, H. 等。延伸器蛋白 1 的二聚化对 Elongator 复合物组装至关重要。Proc. Natl Acad. Sci. USA 112, 10697–10702 (2015)。

    文章  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  45. Huang, B., Johansson, M. J. O. & Byström, A. S. 摆动尿苷 tRNA 修饰的早期步骤需要 Elongator 复合物。RNA 11, 424–436 (2005)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  46. Gaik, M., Kojic, M., Wainwright, B. J. & Glatt, S. Elongator 及其亚复合物在人类疾病中的作用。EMBO Mol. Med. 15, e16418 (2023)。

    文章  PubMed  CAS  Google Scholar 

  47. Laguesse, S. 等。动态未折叠蛋白反应参与皮质神经发生的控制。Dev. Cell 35, 553–567 (2015)。

    文章  PubMed  CAS  Google Scholar 

  48. Noto, D. 等。开发一种从造血细胞诱导小胶质细胞样细胞的培养系统。Neuropathol. Appl. Neurobiol. 40, 697–713 (2014)。

    文章  PubMed  PubMed Central  Google Scholar 

  49. Uenaka, T. 等。定义的人三谱系脑微组织。预印本发表于 bioRxiv https://doi.org/10.1101/2025.08.05.668605 (202)。

  50. Ueki, Y., Ramirez, G., Salcedo, E., Stabio, M. E. & Lefcort, F. Ikbkap 缺失导致家族性自主神经功能障碍小鼠模型中出现缓慢、进行性视网膜变性。eNeuro 3, ENEURO.0143-16.2016 (2016)。

    文章  PubMed  PubMed Central  Google Scholar 

  51. Gaik, M. 等。两个 Elongator 亚复合物在神经发育过程中的功能分化。EMBO Mol. Med. 14, e15608 (2022)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  52. Kojic, M. 等。Elp2 突变扰动表观转录组并导致复杂的神经发育表型。Nat. Commun. 12, 2678 (2021)。

    文章  ADS  MathSciNet  PubMed  PubMed Central  CAS  Google Scholar 

  53. Kojic, M. 等。小鼠中的 Elongator 突变诱导神经退行性变和共济失调样行为。Nat. Commun. 9, 3195 (2018)。

    文章  ADS  PubMed  PubMed Central  Google Scholar 

  54. Chen, D. 等。Elp3 介导的密码子依赖性翻译促进 mTORC2 激活并调控巨噬细胞极化。EMBO J. 41, e109353 (2022)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  55. Rosu, A. 等。tRNA 修饰酶 Elp3 缺失在造血中激活 p53 依赖性抗肿瘤检查点。J. Exp. Med. 218, e20200662 (2021)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  56. Nedialkova, D. D. & Leidel, S. A. 通过 tRNA 修饰优化密码子翻译速率维持蛋白质组完整性。Cell 161, 1606–1618 (2015)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  57. Duncan, C. N. 等。大脑肾上腺脑白质营养不良基因治疗后的血液系统癌症。N. Engl. J. Med. 391, 1287–1301 (2024)。

    文章  PubMed  PubMed Central  CAS  Google Scholar 

  58. Chen, D. 等。使用非清髓策略进行全脑小胶质细胞替换可改善神经系统疾病小鼠模型中的病理。Sci. Transl. Med. 17, eads6111 (2025)。

    文章  PubMed  CAS  Google Scholar 

  59. Korotkevich, G. 等。快速基因集富集分析。预印本发表于 bioRxiv https://doi.org/10.1101/060012 (2021)。

  60. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2——用于基因列表功能富集分析和命名空间转换工具集 g:Profiler 的 R 包。F1000Res. 9, ELIXIR-709 (2020)。

    文章  PubMed  PubMed Central  Google Scholar 

  61. Love, M. I., Huber, W. & Anders, S. 使用 DESeq2 对 RNA-seq 数据的倍数变化和离散度进行调节估计。Genome Biol. 15, 550 (2014)。

    文章  PubMed  PubMed Central  Google Scholar 

  62. Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P. & Kedl, R. M. Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. Cell Immunol. 214, 110–122 (2001).

    Article  PubMed  CAS  Google Scholar 

  63. Jung, S. et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20, 4106–4114 (2000).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Platt, R. J. et al. CRISPR–Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Ruzankina, Y. et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113–126 (2007).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Bennett, F. C. et al. A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170–1183 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Dai, X.-M. et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111–120 (2002).

    Article  PubMed  CAS  Google Scholar 

  68. Hamanaka, S. et al. Generation of transgenic mouse line expressing Kusabira Orange throughout body, including erythrocytes, by random segregation of provirus method. Biochem. Biophys. Res. Commun. 435, 586–591 (2013).

    Article  ADS  PubMed  CAS  Google Scholar 

  69. Wilkinson, A. C., Ishida, R., Nakauchi, H. & Yamazaki, S. Long-term ex vivo expansion of mouse hematopoietic stem cells. Nat. Protoc. 15, 628–648 (2020).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Krencik, R., Weick, J. P., Liu, Y., Zhang, Z.-J. & Zhang, S.-C. Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat. Biotechnol. 29, 528–534 (2011).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. de Majo, M. et al. Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology. Stem Cell Reports 18, 706–719 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  72. Morgens, D. W., Deans, R. M., Li, A. & Bassik, M. C. Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat. Biotechnol. 34, 634–636 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Wilkinson, A. C. et al. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat. Commun. 12, 686 (2021).

    Article  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  74. Red Blood Cell Lysis Buffer. Cold Spring Harb. Protoc. https://doi.org/10.1101/pdb.rec390 (2006).

  75. Young, K. & Morrison, H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ. J. Vis. Exp. https://doi.org/10.3791/57648 (2018).

  76. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).

    Article  PubMed  CAS  Google Scholar 

  77. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. 4, 1184–1191 (2009).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. https://doi.org/10.12688/f1000research.9501.2 (2016).

  80. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  81. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).

    Article  PubMed  CAS  Google Scholar 

  82. Zhang, X. et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat. Protoc. 13, 530–550 (2018).

    Article  PubMed  CAS  Google Scholar 

  83. Barrett, T. et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 41, D991–D995 (2013).

    Article  PubMed  CAS  Google Scholar 

  84. Deutsch, E. W. et al. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 51, D1539–D1548 (2022).

    Article  Google Scholar 

  85. Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank all members of the Wernig Laboratory for discussions throughout the project; A. Lang and M. Vangipuram for administrative support; staff at the FACS Core at the Institute for Stem Cell Biology and Regenerative Medicine, specifically C. Crumpton and C. Pan, and staff at the Stanford Wu Tsai Neuroscience Institute Neuroscience Microscopy Service, specifically G. Wang, for technical support; R. Leib, F. Liu and N. Brown for their technical support for LC–MS/MS; and R. Stanley for the gift of Csf1r−/− (FVB.129×1-Csf1rtm1Ers) mice. This work was supported by the Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University Mass Spectrometry (RRID:SCR_017801) utilizing the Thermo Exploris 480 nanoLC/MS system (RRID:SCR_022215). This work was supported in part by NIH P30 CA124435 utilizing the Stanford Cancer Institute Proteomics/Mass Spectrometry Shared Resource.

Funding

This work was supported by the DISC0-13875 grant from the California Institute for Regenerative Medicine and by the Robert J. Kleberg, Jr and Helen C. Kleberg Foundation. Additional support was provided by the NIH/NIDDK (R01DK117473; to F.L.). M.M.-D.M. was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, MA 8492/1-1). Y.Y. was supported by the New York Stem Cell Foundation Druckenmiller Fellowship (NYSCF-D-F74). A.C.W. acknowledges support from the Wellcome Trust (302479/Z/23/Z). W.L. was supported by the LLHF Fellowship Grant (no. 2025-A-214-FEL) from the Larry L. Hillblom Foundation.

Author information

Authors and Affiliations

  1. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA

    Marius Marc-Daniel Mader, Wanhua Li, Alexa Scavetti, Yongjin Yoo, Gernot Neumayer, Katie Han, Yohei Shibuya, Hiromitsu Nakauchi & Marius Wernig

  2. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

    Marius Marc-Daniel Mader, Wanhua Li, Alexa Scavetti, Yongjin Yoo, Gernot Neumayer, Katie Han, Yohei Shibuya & Marius Wernig

  3. Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Marius Marc-Daniel Mader

  4. Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany

    Marius Marc-Daniel Mader & Marius Marc-Daniel Mader

  5. Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA

    Wanhua Li, Alexa Scavetti, Yongjin Yoo, Gernot Neumayer, Katie Han, Yohei Shibuya & Marius Wernig

  6. Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Marius Marc-Daniel Mader

  7. Department of Neuroscience, Korea University College of Medicine, Seoul, Republic of Korea

    Yongjin Yoo

  8. Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea

    Yongjin Yoo

  9. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

    Michael Haney & Tony Wyss-Coray

  10. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Michael Haney

  11. Department of Biological and Physical Sciences, Montana State University Billings, Billings, MT, USA

    Lynn George

  12. Department of Cell Biology and Neuroscience, Montana State University, Bozeman, MT, USA

    Frances Lefcort

  13. Tikun Therapeutics, Brookeville, MD, USA

    Frances Lefcort

  14. Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA

    Michael Bassik & Hiromitsu Nakauchi

  15. Advanced Research Initiative, Institute of Science Tokyo, Tokyo, Japan

    Hiromitsu Nakauchi

  16. Department of Haematology, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK

    Adam C. Wilkinson

Authors

  1. Marius Marc-Daniel Mader
  2. Wanhua Li
  3. Alexa Scavetti
  4. Yongjin Yoo
  5. Gernot Neumayer
  6. Katie Han
  7. Yohei Shibuya
  8. Michael Haney
  9. Tony Wyss-Coray
  10. Lynn George
  11. Frances Lefcort
  12. Michael Bassik
  13. Hiromitsu Nakauchi
  14. Adam C. Wilkinson
  15. Marius Wernig

Contributions

Study concept and design: M.M.-D.M., M.W. and A.C.W. Animal experiments: M.M.-D.M., A.S., K.H., Y.Y. and Y.S. Cell culture: M.M.-D.M., W.L., A.C.W., Y.S. and A.S. ddPCR: M.M.-D.M. and G.N. Immunostaining, microscopy and image analyses: M.M.-D.M., A.S., W.L. and K.H. Flow cytometry: M.M.-D.M., Y.S. and A.C.W. CRISPR-KO screen: M.M.-D.M., A.C.W., M.H., M.B. and T.W.-C. RNA-seq and proteomic experiments: M.M.-D.M. and Y.S. Data analyses and interpretation: M.M.-D.M., M.W., A.C.W., W.L., F.L., L.G. and H.N. Drafting and major editing of original manuscript: M.M.-D.M. and M.W. All authors reviewed, revised and approved the final version of the paper.

Corresponding author

Correspondence to Marius Wernig.

Ethics declarations

Competing interests

M.W. is a co-founder of Neucyte, a scientific advisor for bit.bio and iPeace, co-founder and scientific advisor of Lytherian Therapeutics and Theseus Therapies. PLX5622 was provided by Plexxikon under a material-transfer agreement between Stanford University and Plexxikon. The other authors declare no competing interests.

Peer review

Peer review information

Nature thanks the anonymous reviewers for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data figures and tables

Extended Data Fig. 1 Additional characterization of cHSPC-derived myeloid cells in the brain.

a, Representative flow cytometric gating for sorting of hematopoietic stem cells for the generation of cHSPC cultures. b, Donor-derived (GFP+) chimerism of CD45+ cells in the peripheral blood assessed via flow cytometry. n = 6 for WBM-graft recipient animals; n = 6 for cHSPC-graft recipient animals. Two-sided Mann–Whitney U test. Box plot definition (applicable to all box plots in this figure): median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers). c, Representative immunofluorescence images of microglia or brain myeloid cells derived from either WBM or cHSPCs at 2 weeks after PLX5622 withdrawal. 8 animals were assessed in total. Scale bars = 30 µm. d, Morphological analysis of brain myeloid cells in cortex and hippocampus. Colors represent different animals. n = 81 cells in total. Two-sided Welch t-test. e, Expression of macrophage self-renewal regulator genes Maf and Mafb. n = 13 biological replicates total (n = 4 biological replicates in the MG group, n = 3 biological replicates per WBM, pHSC, and cHSPC group). f, Top 25 significantly (padj <0.05; based on DESeq2 DEG analysis using default two-sided Wald test with Benjamini-Hochberg adjustment)61 up & downregulated genes between MG and cHSPC-derived myeloid cells (heatmap is scaled row-wise). n = 13 biological replicates total.

Source data

Extended Data Fig. 2 Additional flow cytometric and histological characterization of in vitro cHSPC-derived myeloid cells.

a, Flow cytometric quantification of the absolute myeloid cell number per well (based on CD11b+ CD45+ gate). Cells were plated on 1.9 cm2 CellBIND plates either with or without PLX5622 pretreated C57BL/6 J glia and maintained in MG-medium supplemented with 10% FBS for 14 days with 50% medium changes twice a week. Absolute count calculation based on counting beads. n = 4 technical replicates (culture wells) per group (n = 16 total). Box plot definition (applicable to all box plots in this figure): median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers). b, Flow cytometric assessment of the effects of pretreatment of glia with PLX5622 and addition of FBS on myeloid cell generation. Co-cultures were analyzed 14 days after initiation (cHSPC plating number = 0.2 × 103). n = 5 technical replicates (culture wells) per group. Two-sided Welch t-test. c, Co-cultures were analyzed either 14 days (1 × 103 plated cHSPC) or 10 days (0.2 × 103 plated cHSPC) after initiation. Surface of primary glia was 1.9 cm2. n = 3 technical replicates (culture wells) per condition. Two-sided Welch t-test. d, Flow cytometric quantification of the myeloid fraction in culture with or without plated cHSPCs (C57BL/6 J primary glia with or without PLX5622 pretreatment). Evaluated after 14 days. n = 3 technical replicates (culture wells) per condition. e, Representative immunofluorescence images of in vitro cHSPC-derived myeloid cells or primary microglia with different FBS and PLX5622 pretreatment conditions. Evaluated in 3 technical replicates (culture wells) per condition. Scale bars = 200 µm.

Source data

Extended Data Fig. 3 Different temporal stages of myeloid differentiation in cHSPC-glia cocultures.

a, Immunofluorescence images of cHSPC-glia co-cultures 1, 3, or 7 days after initiation. Yellow circles indicate GFP+ Ki67+ cells. Blue circles indicate early processes and red circle indicate early Iba1 expression present in day-3 cHSPC-derived myeloid cells. Scale bars = 100 µm. Experiment performed with 3 technical replicates (culture wells).

Extended Data Fig. 4 Additional transcriptional characterization of in vitro cHSPC-derived myeloid cells.

a, Hierarchical clustering based on Euclidean distance using the top 2500 variant genes. n = 4 technical replicates per group. b, Venn diagrams of significantly (padj <0.05, based on DESeq2 DEG analysis using default two-sided Wald test with Benjamini-Hochberg adjustment)61 DEGs compared to cHSPCs. Upregulated: log2 fold change > 1; Downregulated: log2 fold change < −1. c, Volcano plot of genes returned by marker gene analysis for d2.HDMC with unidirectional change (log2 fold change consistently either >0 or <0 compared to all other groups). Red color indicates upregulated (139 genes; padj <0.05; log2 fold change > 1) and blue downregulated (114 genes; padj <0.05; log2 fold change < −1) genes. DESeq2-derived p values (two-sided Wald test with Benjamini-Hochberg adjustment) resulting from pairwise comparisons across conditions were combined per gene using Berger’s intersection-union test (combineMarkers, scran, pval.type = “all”; Benjamini-Hochberg adjustment). d, Expression of selected proliferation genes. n = 4 technical replicates per group. Adjusted p values derived from DESeq2 DEG analysis (two-sided Wald tests with Benjamini-Hochberg adjustment). Box plot definition: median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers).

Source data

Extended Data Fig. 5 Confirmatory experiments on the Elp1 knockout phenotype on myeloid cell repopulation in vitro and in vivo.

a, Competition assay: KUO cHSPCs were edited via RNP CRISPR-KO. Edited KUO cHSPCs were co-cultured on PLX5622 pretreated primary glia together with UBC-GFP non-edited control cHSPCs at consistent plating numbers (100 + 100 cHSPCs) for 13 days and then analyzed via flow cytometry. b, Quantification of the fraction of KUO+ (edited) cells within the overall population of grafted myeloid cells (CD45+ CD11b+ and either KUO+ or GFP+). The control group represented non-edited KUO cells. The fractions were normalized to the mean fraction of the control group. Red diamonds represent the respective indel rate per sgRNA. n = 5 technical replicates (culture wells) per group. Two-sided Welch t-test. Box plot definition (applicable to all box plots in this figure): median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers). c, Elp1flox/flox;UBC-CreER+/− or UBC-GFP cHSPCs were pretreated either with 4OH-tamoxifen (T) or vehicle (V). Cells were then plated (á 300 cells per well) on CSF1R-KO glia for 10 days (serum free condition), followed by flow cytometric analysis. Fractions were normalized to the mean fraction of the vehicle/vehicle condition. n = 6 technical replicates (culture wells) per condition. Two-sided Welch t-test. d, Competitive transplantation of whole bone marrow donor cells (total of 10 million / recipient) derived from either Elp1flox/flox;UBC-CreER+/− or Elp1flox/flox;UBC-CreER−/− male mice mixed in equal numbers with UBC-GFP bone marrow (all CD45.2) after 5 day tamoxifen treatment of all donor animals into busulfan-conditioned wildtype B6-CD45.1 mice. After 1 week, recipient animals were provided with PLX3397 chow for 3 weeks. Analysis was performed 2 weeks after PLX3397 withdrawal. e, GFP+ chimerism of different CD45.2+ cell fractions based on flow cytometry 6 weeks after bone marrow transplantation. n = 3 animals per group. Two-sided Welch t-test. f, Representative flow cytometry plots for GFP+ chimerism. Illustrations in a and d adapted from refs. 3,24, Springer Nature.

Source data

Extended Data Fig. 6 Impact of Elp1 knockout on in vivo hematopoiesis.

a, Wildtype B6-CD45.1 mice received busulfan-conditioned bone marrow transplantations with donor cells derived from Elp1flox/flox;UBC-CreER+/− (CD45.2) mice. After ~10 weeks, recipient animals were treated with or without tamoxifen and were analyzed 1 week after the last injection. n = 4 animals per group. b, Quantification of donor derived chimerism. n = 8 animals in total. Two-sided Welch t-test. Box plot definition (applicable to all box plots in this figure): median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers). c, ddPCR-based quantification of Elp1 knockout efficiency in the bone marrow. n = 8 animals in total. Two-sided Welch t-test. d, Flow cytometric gating strategies for the analysis of peripheral blood and bone marrow. e, Fraction of different peripheral blood cells. n = 8 animals in total. Two-sided Welch t-test. f, Flow cytometric analysis of blood myeloid cells for Ly6C expression. n = 8 animals in total. Two-sided Welch t-test. g, Absolute donor derived cell count in the combined leg bones per animal. Based on multiplication of the absolute bone marrow cell count with the percentage of donor-derived chimerism. n = 8 animals in total. Two-sided Welch t-test. h, Relative frequency of LIN− subpopulations. n = 8 animals in total. Two-sided Welch t-test. i, Relative frequency of LIN− CD127− cKit+ Sca1− subpopulations. n = 8 animals in total. Two-sided Welch t-test. j, Flow cytometric gating strategies for the analysis of peripheral blood and bone marrow and representative flow cytometry plots for GFP+ chimerism 6 weeks after tamoxifen injections. Illustrations in a adapted from refs. 3,24, Springer Nature.

Source data

Extended Data Fig. 7 Supporting information on the persistence of differentiated myeloid cells after Elp1 knockout.

a, Wildtype B6-CD45.1 mice received busulfan-conditioned bone marrow transplantations with donor cells derived from Elp1flox/flox;UBC-CreER+/− mice, followed by PLX3397 diet after one week for 3 weeks. ~8 months after PLX3397 withdrawal, recipient animals were treated with or without tamoxifen and analyzed after another ~4 weeks. Representative flow cytometry plots and quantification. n = 4 animals with tamoxifen, n = 3 animals with vehicle. Two-sided Welch t-test. Box plot definition (applicable to all box plots in this figure): median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers). b, Elp1flox/flox;CX3CR1-CreER+/− or Elp1flox/flox;CX3CR1-CreER−/− mice were treated with tamoxifen for an initial 5 days followed by continuous injections three times weekly. Flow cytometric analysis was performed ~7 weeks after tamoxifen initiation. n = 6 animals per group (each consisting of 2 males and 4 females). Two-sided Welch t-test. c, Flow cytometric analysis of brain cells in wildtype C57BL/6 J animals treated with PLX3397 (i.p. 92 mg/kg/d for 7 days). n = 5 animals in total.

Source data

Extended Data Fig. 8 Additional molecular characterization of early Elp1-deficient myeloid differentiation.

a, Protein expression of Actin beta and Elp1 based on LC-MS/MS. Shown are normalized iBAQ values. Missing values were set to 0. n = 4 biological replicates per group. Box plot definition (applicable to all box plots in this figure): median (center line), first and third quartiles (lower and upper hinges), smallest/highest value with at most 1.5*IQR from the hinge (whiskers). b, Number of detected proteins per sample after filtering and normalization. The dotted line shows the number of uniquely identified proteins over all samples. P value based on two-sided Welch t-test between the two experimental groups. c, Correlation between RNA (shown as FPKM values) and protein expression (shown as filtered normalized iBAQ values) for the two experimental groups. Colors represent different biological replicates. R = Pearson correlation coefficient. n = 4 biological replicates per group. Two-sided test. d, WGNCA module eigengene expression compared between the experimental conditions. n = 4 biological replicates per group. Two-sided Welch t-test with Holm p value adjustment. e, Top 30 hub genes of WGNCA module 9. Genes that are significant DEGs are labeled in red. f, Gene set enrichment for UPR. Based on genes underlying the WGNCA analysis ranked by Module Membership to module 9 (fgsea R package59, adaptive multi-level split Monte-Carlo p value estimation; two-sided test, Benjamini-Hochberg adjustment. g, Significantly differentially expressed proteins (padj <0.05; based on DEP package using a two-sided moderated t-test [limma] with FDR correction) between the experimental groups. Heatmap is scaled row-wise. Missing values have been assigned the color grey. n = 4 biological replicates per group.

Source data

Extended Data Fig. 9 Human myeloid cell repopulation is Elp1 dependent.

a, Human CD34+ cells from either mobilized peripheral blood or cord blood were co-cultured with human iPSC-derived astrocytes. b, Representative immunofluorescence images of co-cultures after 21 days. Scale bars = 100 µm. N = 2 different peripheral blood and N = 4 different cord blood samples. c, Human cord blood CD34+ cells were edited using RNP-mediated Cas9 knockout, targeting the CLYBL or ELP1 loci. d, ELP1 indel rate. Measured on day 5 or 6 after editing. N = 4 biological replicates. Box plot definition see Fig. 1. e, Representative immunofluorescence images of co-cultures after 21 days. Scale bars = 100 µm. N = 4 different cord blood samples. f, Quantification of myeloid cells in the co-culture after 21 days. Iba1+ cells were counted in 2-3 regions of interest (each 5325 µm2) per sample and averaged. Numbers were normalized between matched samples (i.e. derived from the same cord blood) using CLYBL as the reference. N = 4 biological replicates. Two-sided Welch t-test. Illustrations in a and c adapted from refs. 3,24, Springer Nature.

Source data

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mader, M.MD., Li, W., Scavetti, A. et al. Elp1 is required for myeloid differentiation and brain repopulation. Nature (2026). https://doi.org/10.1038/s41586-026-11112-3

Download citation

  • Received: 12 April 2024

  • Accepted: 01 September 2026

  • Published: 14 October 2026

  • Version of record: 14 October 2026

  • DOI: https://doi.org/10.1038/s41586-026-11112-3

来源：Nature 干细胞主题 · nature.com

干细胞CIRM#论文/研究#干细胞#基础研究#临床前研究#CIRM